Jump to content

Deploying a Fully Integrated Biologics Database at ADC Therapeutics

In this webinar, learn how ADC Therapeutics is streamlining the entire Antibody-Drug Conjugate (ADC) R&D process by using a central E2E digital backbone that enables the registration and tracking of both complex biologics and small molecules, integrating analytics and functional assay results into a ‘single source of truth’ across R&D, which significantly improves the throughput and efficiency of ADC discovery.

Christopher Gallagher, Ph.D., Associate Director at ADC Therapeutics (ADCT) will share how Genedata Biologics® digitalizes and automates processes across ADC discovery — from antibody engineering to expression, purification, chemistry and conjugation, cell biology, and ADC characterization and QC.

Get Insights On:

  • The entire process of ADC development from antibody engineering, expression, purification, and bioconjugation to characterization
  • Enhancing discovery through comprehensive registration and tracking of all ADCs and their unique components including antibodies, linkers, payloads, DAR, and conjugation sites
  • Capturing, analyzing, and visualizing in vitro and in vivo characterization data, including toxicology and PK studies, to more efficiently evaluate ADC batches
  • Streamlining the ADC discovery process by integrating registration, analytics, functional assay results, and visualizations in a single source of truth

 


Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy